Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PTAB Knocks Out Two Copaxone 40 mg Patents

Executive Summary

Patent Trial and Appeal Board finds claims in '250 and '413 patents covering 40 mg dosage are unpatentable, giving generic manufacturers a chance at early entry once FDA approves ANDAs.


Related Content

Fate Of Copaxone 40mg Patents Depends On Courts After PTAB Rejection
Stockwatch: Teva And Mylan Hit Terminal Velocity
Mylan Sees A Difference In Having Generic Drug User Fees
Mylan Scores PTAB Review Of Teva’s Copaxone Patents


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts